# Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients

> **NCT00097032** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 30 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** risperidone; quetiapine

## Key facts

- **NCT ID:** NCT00097032
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** 2005-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2011-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00097032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00097032, "Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00097032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*